EHA 2018 | Restarting the apoptotic pathway in myeloma cells

Shaji Kumar

Many tumor cells are able to evade apoptosis, with the potential to survive in the body indefinitely. Here, Shaji Kumar, MD, of the Mayo Clinic, Rochester, MN, explains some of the mutations that allow this to happen and highlights the need for therapies that target these anti-apoptotic pathways. Dr Kumar mentions clinical trials that are investigating the use of venetoclax to re-initiate apoptosis in multiple myeloma (MM). This interview was recorded at 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter